1. Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report
- Author
-
Elżbieta Urbanowska, Wieslaw Wiktor-Jedrzejczak, Beata Gierej, Magdalena Tormanowska, Kazimierz Hałaburda, Jadwiga Dwilewicz-Trojaczek, Ewa Karakulska-Prystupiuk, Joanna Drozd-Sokołowska, Grzegorz W. Basak, and Wojciech Sachs
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Transplantation Conditioning ,Myeloid ,Cyclophosphamide ,medicine.medical_treatment ,Hematopoietic stem cell transplantation ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Busulfan ,Melphalan ,Salvage Therapy ,Transplantation ,Mitoxantrone ,business.industry ,Cytarabine ,Hematopoietic Stem Cell Transplantation ,Induction chemotherapy ,Myeloid leukemia ,Induction Chemotherapy ,medicine.disease ,Leukemia, Myeloid, Acute ,Leukemia ,medicine.anatomical_structure ,Cladribine ,Female ,Surgery ,business ,medicine.drug - Abstract
Background Primary refractory acute myeloid leukemia (AML) is associated with dismal prognosis. No standard treatment options are available, and it remains an unmet clinical need. Here, we report a case of a tandem allogeneic hematopoietic stem cell transplantation (allo-HSCT) performed in a patient who did not achieve remission after 2 courses of induction chemotherapy. Methods Case report The treatment was approved by the Bioethical Commission of the Medical University of Warsaw and was performed in accordance with the Declaration of Helsinki. The patient gave informed consent. Results A 41-year-old woman was diagnosed with AML, high cytogenetic risk, with concomitant skin and central nervous system involvement, bone marrow necrosis, and hemophagocytic lymphohistiocytosis. She received “3+7” induction and HAM (cytarabine, mitoxantrone) reinduction, after which she did not achieve remission and hematopoietic recovery. Tandem allo-HSCT was performed from the same HLA-identical brother---the first after reduced intensity conditioning (cladribine, cytarabine, mitoxantrone, melphalan) and the second after myeloablative conditioning (BuCy--busulphan, cyclophosphamide). The patient obtained complete remission after the first allo-HSCT and remains disease-free after the second for 5 years Conclusion Tandem allo-HSCT may be a treatment option for primary refractory AML.
- Published
- 2020